Blockbuster Enhertu may get tumor agnostic label, targeting any HER2-expressing cancer: GlobalData Read more
Enhertu improves both progression-free and overall survival in Destiny-Breast04 trial in patients with HER2-low metastatic breast cancer Read more
ENHERTU (fam-trastuzumab deruxtecan-nxki) gets US FDA nod for HER2-positive advanced gastric cancer Read more